A novel antimetabolite: TAS-102 for metastatic colorectal cancer.
Miyamoto Y, Lenz HJ, Baba H.
Expert Rev Clin Pharmacol · research support, non-u.s. gov't; research-article; review; journal article · DOI 10.1586/17512433.2016.1133285 PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för Lonsurf. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
20 hitsTAS-102 an Emerging Oral Fluoropyrimidine.
Chen J, Han M, Saif MW.
Anticancer Res · review; journal articleTAS-102: a novel antimetabolite for the 21st century.
Uboha N, Hochster HS.
Future Oncol · review-article; review; journal article · DOI 10.2217/fon.15.276Safety and Efficacy of Trifluridine/Tipiracil Monotherapy in Clinical Practice for Patients With Metastatic Colorectal Cancer: Experience at a Single Institution.
Kotani D, Shitara K, Kawazoe A, Fukuoka S, Kuboki Y, Bando H, Okamoto W, Kojima T, Doi T, Ohtsu A, Yoshino T.
Clin Colorectal Cancer · journal article · DOI 10.1016/j.clcc.2015.11.005Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignancies.
Peters GJ.
Ther Adv Med Oncol · review-article; review; journal article · DOI 10.1177/1758834015603313Pharmaceutical Approval Update.
Gohil K.
P T · other; journal articleTAS-102 for the treatment of metastatic colorectal cancer.
Salvatore L, Rossini D, Moretto R, Cremolini C, Schirripa M, Antoniotti C, Marmorino F, Loupakis F, Falcone A, Masi G.
Expert Rev Anticancer Ther · review; journal article · DOI 10.1586/14737140.2015.1105746[Short-Term Outcome of TAS-102 for Refractory Metastatic Colorectal Cancer].
Yoshimatsu K, Yokomizo H, Nakayama M, Okayama S, Satake M, Sakuma A, Yano Y, Matsumoto A, Fujimoto T, Usui T, Yamaguchi K, Shiozawa S, Shimakawa T, Katsube T, Naritaka Y.
Gan To Kagaku Ryoho · journal articleNew Medical Devices.
Författaruppgift saknas
P T · news; journal articlePhase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer.
Bendell JC, Rosen LS, Mayer RJ, Goldman JW, Infante JR, Benedetti F, Lin D, Mizuguchi H, Zergebel C, Patel MR.
Cancer Chemother Pharmacol · research support, non-u.s. gov't; research-article; multicenter study; clinical trial, phase i; journal article · DOI 10.1007/s00280-015-2850-4Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts.
Nukatsuka M, Nakagawa F, Takechi T.
Anticancer Res · journal articlePhase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer.
Doi T, Yoshino T, Fuse N, Boku N, Yamazaki K, Koizumi W, Shimada K, Takinishi Y, Ohtsu A.
Invest New Drugs · research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article · DOI 10.1007/s10637-015-0271-1[Initial Evaluation of the Efficacy and Safety of Tablets Containing Trifluridine and Tipiracil Hydrochloride--Safety Measures Devised by a Multidisciplinary Team Including a Pharmaceutical Outpatient Clinic].
Aimono Y, Kamoshida T, Sakamoto R, Nemoto M, Saito Y, Aoyama Y, Maruyama T.
Gan To Kagaku Ryoho · journal article; english abstractTAS-102, a novel antitumor agent: a review of the mechanism of action.
Lenz HJ, Stintzing S, Loupakis F.
Cancer Treat Rev · research support, non-u.s. gov't; research-article; review; journal article · DOI 10.1016/j.ctrv.2015.06.001Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, Sobrero A, Boucher E, Peeters M, Tran B, Lenz HJ, Zaniboni A, Hochster H, Cleary JM, Prenen H, Benedetti F, Mizuguchi H, Makris L, Ito M, Ohtsu A, RECOURSE Study Group.
N Engl J Med · clinical trial, phase iii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1056/nejmoa1414325Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts.
Tsukihara H, Nakagawa F, Sakamoto K, Ishida K, Tanaka N, Okabe H, Uchida J, Matsuo K, Takechi T.
Oncol Rep · research-article; journal article · DOI 10.3892/or.2015.3876Positron emission tomography imaging of human colon cancer xenografts in mice with [18F]fluorothymidine after TAS-102 treatment.
Lee HJ, Oh SJ, Lee EJ, Chung JH, Kim Y, Ryu JS, Kim SY, Lee SJ, Moon DH, Kim TW.
Cancer Chemother Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1007/s00280-015-2718-7Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, with irinotecan hydrochloride on human colorectal and gastric cancer xenografts.
Nukatsuka M, Nakagawa F, Saito H, Sakata M, Uchida J, Takechi T.
Anticancer Res · journal article[Efficacy of TAS-102].
Kotani D, Fukuoka S, Yoshino T.
Gan To Kagaku Ryoho · review; journal articleRepeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models.
Tanaka N, Sakamoto K, Okabe H, Fujioka A, Yamamura K, Nakagawa F, Nagase H, Yokogawa T, Oguchi K, Ishida K, Osada A, Kazuno H, Yamada Y, Matsuo K.
Oncol Rep · research-article; journal article · DOI 10.3892/or.2014.3487